Vitamin D Supplementation Reduces Respiratory Infections in Asthma Patients by Boosting the Antimicrobial Peptide Cathelicidin

Randomized, placebo-controlled trial with 86 asthma patients aged 18-50. Both groups received standard GINA-recommended asthma treatment. The treatment group additionally received calcitriol (1,25-(OH)₂D₃) for 6 months. At baseline and 6 months, researchers performed skin prick tests, pharyngeal bacterial cultures, sputum cathelicidin LL-37 measurements, and serum quantification of IgE, eosinophils, IL-5, IL-9, IL-10, IL-13, and IFNγ.

Respiratory infections are a leading trigger of asthma exacerbations. Finding that vitamin D can reduce infections by boosting the body's own antimicrobial peptide (cathelicidin LL-37) provides a mechanistic explanation for vitamin D's protective effects and suggests a simple, low-cost adjunct therapy that could improve outcomes for asthma patients.

Cathelicidin LL-37 is one of the most studied antimicrobial peptides in humans, with broad activity against bacteria, viruses, and fungi. This study connects vitamin D's well-known immune benefits to a specific peptide mechanism — the upregulation of LL-37. This finding fits into a larger body of research exploring how endogenous antimicrobial peptides contribute to immune defense and how their production can be therapeutically modulated.

The sample size of 86 patients is moderate, and the study may not be powered to detect all relevant effects. Allergen sensitivity did not change, suggesting vitamin D's benefits may be limited to infection-related rather than allergic aspects of asthma. The study used calcitriol (active vitamin D) rather than standard vitamin D3 supplements, which may limit generalizability to typical supplementation regimens. Long-term effects beyond 6 months were not assessed.